MDM2 and neoplasm: In human p53 wild-type tumor cells, NVP-CGM097 binds to human MDM2 protein with a Ki value of 1.3 nM, activating p53 in human cells and inducing p53-dependent cell cycle arrest and apoptosis.389,390 In January 2013, NVP-CGM097 was enrolled in a phase I clinical trial (NCT01760525) to evaluate the dose-escalation study of NVP-CGM097 in adults with advanced solid tumors.